PharmaEssentia Corporation (6446.TW) News
Follow PharmaEssentia Corporation (6446.TW) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 2 public stories across 1 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
H
From Taiwan to the World: PharmaEssentia Expands Global Reach With New Drug Approvals, Overseas Investments
For best results when printing this announcement, please click on link below: From Taiwan to the World: PharmaEssentia Expands Global Reach With New Drug Approvals, Overseas Investments PharmaEssentia Corporation (TWSE:
GEOPOLITICS | Oct 16, 2026, 12:17 PM UTC
L
PharmaEssentia Wins US, Japan Approvals for Ropeg to Treat Essential Thrombocythemia
PharmaEssentia secured US and Japanese approvals in August for BESREMi (ropeginterferon alfa-2b) to treat essential thrombocythemia. BESREMi is the only FDA-approved drug for both essential thrombocythemia and polycythem
REGULATION | Oct 16, 2026, 12:13 PM UTC